1
项与 JNJ-90301900 相关的临床试验A Phase 2, Randomized, Open-Label, Active-Controlled Study of JNJ-90301900 in Combination With Chemoradiation Followed by Durvalumab in Locally Advanced and Unresectable Stage III NSCLC
The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.
100 项与 JNJ-90301900 相关的临床结果
100 项与 JNJ-90301900 相关的转化医学
100 项与 JNJ-90301900 相关的专利(医药)
100 项与 JNJ-90301900 相关的药物交易